Kaplan Fox Notifies Medline Inc. (MDLN) Investors of a Securities Investigation into the Company

New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Medline investor and have suffered losses, or if you have information that could assist in the Medline investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. On June 2, 2026, the Federal Drug Administration ("FDA") published a warning letter dated May 28, 2026 addressed to Medline summarizing "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals[.]" The FDA further states that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." Following this news, the price of Medline stock fell $2.56 per share, or 7.16%, to close at $33.19 per share on June 2, 2026. According to a June 3, 2026 Reuters article, the latest FDA warning letter relates to "violations of manufacturing quality standards" and is "the second such action against the [C]ompany in two months." Further, the Reuters article states that according to the FDA, "the Company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices." WHY CONTACT KAPLAN FOX? Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented. Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America —the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors , and a $475 million settlement in In re Merrill Lynch . For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this investigation, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1501 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. https://www.kaplanfox.com/case/medline-inc-class-action-alert-learn-more-now/ To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312524 Source: Kaplan Fox & Kilsheimer LLP